The benefits and risks of testosterone replacement therapy: a review

Nazem Bassil, Saad Alkaade, John E Morley, Nazem Bassil, Saad Alkaade, John E Morley

Abstract

Increased longevity and population aging will increase the number of men with late onset hypogonadism. It is a common condition, but often underdiagnosed and undertreated. The indication of testosterone-replacement therapy (TRT) treatment requires the presence of low testosterone level, and symptoms and signs of hypogonadism. Although controversy remains regarding indications for testosterone supplementation in aging men due to lack of large-scale, long-term studies assessing the benefits and risks of testosterone-replacement therapy in men, reports indicate that TRT may produce a wide range of benefits for men with hypogonadism that include improvement in libido and sexual function, bone density, muscle mass, body composition, mood, erythropoiesis, cognition, quality of life and cardiovascular disease. Perhaps the most controversial area is the issue of risk, especially possible stimulation of prostate cancer by testosterone, even though no evidence to support this risk exists. Other possible risks include worsening symptoms of benign prostatic hypertrophy, liver toxicity, hyperviscosity, erythrocytosis, worsening untreated sleep apnea or severe heart failure. Despite this controversy, testosterone supplementation in the United States has increased substantially over the past several years. The physician should discuss with the patient the potential benefits and risks of TRT. The purpose of this review is to discuss what is known and not known regarding the benefits and risks of TRT.

Keywords: cardiovascular disease; erectile dysfunction; hypogonadism; osteoporosis; testosterone replacement therapy.

Figures

Figure 1
Figure 1
Approach to the diagnosis and treatment of late onset hypogonadism (ADAM = St. Louis University Androgen Deficiency in Aging Males Questionnaire).

References

    1. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2005;8:56–58.
    1. Morales A, Schulman CC, Tostain J, Wu FCW. Testosterone deficiency syndrome (TDS) needs to be named appropriately – the importance of accurate terminology. Eur Urol. 2006;50:407–409.
    1. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482–492.
    1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724–731.
    1. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–1299.
    1. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68–75.
    1. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036–1041.
    1. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study Circulation 2007. 4116232694–2701.
    1. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660–1665.
    1. Araujo A, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Intern Med. 2007;167:1252–1260.
    1. Lindeman RD, Yau CL, Baumgartner RN, Morley JE, Garry PJ. New Mexico Aging Process Study. Longitudinal study of fasting serum glucose concentrations in healthy elderly. The New Mexico Aging Process Study. J Nutr Health Aging. 2003;7(3):172–177.
    1. Vermeulen A. Androgen replacement therapy in the aging male – a critical evaluation. J Clin Endocrinol Metab. 2001;86:2380–390.
    1. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl. 2001;22:718–731.
    1. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589–598.
    1. Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab. 2007;92:3599–3603.
    1. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol in older men. J Clin Endocrinol Metab. 2006;91:1336–1344.
    1. Yeap BB, Almeida OP, Hyde Z, et al. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007;156:585–594.
    1. Krithivas K, Yurgalevitch SM, Mohr BA, et al. Evidence that the CAG repeat in the androgen receptor is associated with age related decline in serum androgens levels in men. J Endocrinol. 1999;162:137–142.
    1. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle age men: a 13 year follow-up of former Multiple Risk Factors Intervention Trial participants. Am J Epidemiol. 1997;46:609–617.
    1. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016–1025.
    1. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–4247.
    1. Wu FCW, Tajar A, Pye SR, et al. Hypothalamic–pituitary–testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European Male Aging Study. J Clin Endocrinol Metab. 2008;93:2737–2745.
    1. Veldhuis JD. Aging and hormones of the hypothalamo–pituitary axis: gonadotropic axis in men and somatotropic axes in men and women. Ageing Res Rev. 2008;7:189–208.
    1. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833–876.
    1. Morales A, Spevack M, Emerson L, et al. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male. 2007;10:57–65.
    1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995–2010.
    1. Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med. 1991;53:363–374.
    1. Travison TG, Morley JE, Araujo AB, O’Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. 2006;91:2509–2513.
    1. Morley JE, Kim MJ, Haren MT, Kevorkian R, Banks WA. Frailty and the aging male. Aging Male. 2005;8:135–140.
    1. Baum N, Candace A, Crespi CA. Testosterone replacement in elderly men. Testosterone replacement in elderly men. Geriatrics. 2007;62:15–18.
    1. Shores MM, Moceri VM, Sloan KL, Matsumoto AM, Kivlahan DR. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Pyschiatry. 2005;66:7–14.
    1. Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male. 2005;8:59–74.
    1. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001;137:231–243.
    1. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91:4335–4343.
    1. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–1242.
    1. Morley JE, Perry HM, III, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006;53:424–429.
    1. Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the Aging Males’ Symptoms (AMS) scale predict those of screening scales for androgen deficiency. Aging Male. 2004;7:211–218.
    1. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol. 2004;46:80–87.
    1. T’Sjoen G, Goemaere S, De Meyere M, Kaufman JM. Perception of males’ aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology. 2004;29:201–214.
    1. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004;89:3813–3817.
    1. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol. 2005;63:601–602.
    1. Morley JE, Melmed S. Gonadal dysfunction in systematic disorders. Metabolism. 1979;28:1051–1073.
    1. Matsumoto AM. Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol Med Sci. 2002;57:76–99.
    1. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003;58:710–717.
    1. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159:507–514.
    1. Citron JT, Ettinger B, Rubinoff H, et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol. 1996;155:529–533.
    1. Bunch TJ, Abraham D, Wang S, Meikle AW. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male. 2002;5:38–46.
    1. Rhoden EL, Estrada C, Levine L, Morgentaler A. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol. 2003;170:795–798.
    1. Buvat J, Lemaire A. Endocrine screening in 1, 022 men with erectile dysfunction clinical significance and cost effective strategy. J Urol. 1997;158:1764–1767.
    1. Araujo AB, O’Donnell A, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920–5926.
    1. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005;28:28–31.
    1. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85:3276–3282.
    1. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405–13.
    1. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672.
    1. Wang C, Plymate S, Nieschlag E, Paulsen CA. Salivary testosterone in men: further evidence of a direct correlation with free serum testosterone. J Clin Endocrinol Metab. 1981;53:1021–1024.
    1. Morley JE, Perry HM, III, Patrick P, Dollbaum CM, Kells JM. Validation of salivary testosterone as a screening test for male hypogonadism. Aging Male. 2006;9:165–169.
    1. Gonacharov N, Katsya G, Dobracheva A, Nizhnik A, Kolesnikova G, Herbst V, Westermann J. Diagnostic significance of free salivary testosterone measurement using a direct luminescence immunoassay in healthy men and in patients with disorders of androgenic status. Aging Male. 2006;9:111–122.
    1. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–1457.
    1. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005;14:2257–2260.
    1. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92:3844–3853.
    1. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi’s anemia and non-Fanconi’s conditions. Am J Hematol. 2004;77(3):257–267.
    1. Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. EurUrol. 2005;47:308–312.
    1. McClure RD, Oses R, Ernest ML. Hypogonadal impotence treated by transdermal testosterone. Urology. 1991;37(3):224.
    1. Bhasin S, Bremner WJ. Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab. 1997;82:3–8.
    1. Comhaire FH. Andropause: hormone replacement therapy in the aging male. EurUrol. 2000;38:655–662.
    1. Von Eckardstein, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl. 2002;23(3):419–425.
    1. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839–2853.
    1. Yu Z, Gupta SK, Hwang SS, et al. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. J Clin Pharmacol. 1997;37:1139–1145.
    1. Kim MK, Zhao H, Lee CH, Kim DD. Formulation of a reservoir-type testosterone transdermal delivery system. Int J Pharm. 2001;219(1–2):51–59.
    1. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91:69–74.
    1. Salehian B, Wang C, Alexander G, et al. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate – a clinical research center study. J Clin Endocrinol Metab. 1995;80:3567–3575.
    1. Korbonits M, Slawik M, Cullen D, Ross RJ. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab. 2004;89:2039–2043.
    1. Ross CN, French JA, Patera KJ. Intensity of aggressive interactions modulates testosterone in male marmosets. Physiol Behav. 2004;83(3):437–445.
    1. Wang C, Swerdloff R, Kipnes M, Matsumoto AM. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3821–3829.
    1. Jockenhovel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol. 1996;45:61–71.
    1. Kelleher S, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol. 2001;55:531–536.
    1. Handelsman DJ. Clinical pharmacology of testosterone pellet implants. In: Nieschlag E, Behre HM, editors. Testosterone action deficiency substitution. 2nd ed. Berlin: Springer-Verlag; 1998. pp. 349–364.
    1. Lyngdorf P, Hemmingsen L. Epidemiology of erectile dysfunction and its risk factors: a practice-based study in Denmark. Int J Impot Res. 2004;16:105–111.
    1. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151–157.
    1. Schiavi RC, Schreiner-Engel P, White D, Mandeli J. Pituitary-gonadal function during sleep in men with hypoactive sexual desire and in normal controls. Psychosomat Med. 1988;50:304–318.
    1. Nilsson P, Moller L, Solkad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle aged males. J Intern Med. 1995;237:479–486.
    1. Schiavi RC, Rehman J. Sexuality and aging. Urol Clin North Am. 1995;22:711–726.
    1. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005;90:3838–3846.
    1. Morales A, Buvat J, Gooren LJ, et al. Endocrine aspects of sexual dysfunction in men. J Sex Med. 2004;1:69–81.
    1. Yassin AA, Saad F. Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrologia. 2006;38:34–37.
    1. Liverman CT, Blazer DG, editors. Testosterone and aging: clinical research directions. Washington, DC: Institute of Medicine. The National Academies Press; 2004.
    1. Krause W, Mueller U, Mazur A. Testosterone supplementation in the aging male: which questions have been answered? Aging Male. 2005;8:31–38.
    1. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997;82:3793.
    1. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol. 1997;15:21–26.
    1. Morley JE, Perry HM, Kaiser FE, et al. Effect of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc. 1993;41:149–152.
    1. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;63:641–646.
    1. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647–2653.
    1. Meikle AW, Arver S, Dobs AS, Sanders SW, Mazer NA. Androderm: A permeation-enhanced, non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: Bhasin, editor. Pharmacology, biology, and clinical applications of androgens. New York, NY: Wiley Liss, Inc; 1996. pp. 449–457.
    1. Corona G, Petrone L, Fisher AD, Mansani R, Bandini E. Six-month administration of 1% testosterone gel is able to restore erectile function in hypogonadal patients with erectile dysfunction. Arch Ital Urol Androl. 2008;80(3):103–108.
    1. Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: Can a case be made for a 3-month therapeutic trial? BJU Int. 2004;94:1066–1070.
    1. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658–663.
    1. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol. 2005;173:530–532.
    1. Behre HM. Testosterone and erection. In: Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Cambridge: Cambridge University Press; 2004. pp. 333–346.
    1. Kalintchenko SY, Kozlov GI, Gontcharov NP, et al. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 2003;6:94–99.
    1. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol. 2006;50:940–947.
    1. Aversa A, Isidori AM, Greco EA, Giannetta E, Gianfrilli D, Spera E, et al. Hormonal supplementation and erectile dysfunction. Eur Urol. 2004;45:535–538.
    1. Miner M, Canty DJ, Shabsigh R. Testosterone replacement therapy. Postgrad Med. 2008;120(3):130–153.
    1. Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male. 2008;11(3):146–149.
    1. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab. 2001;86:2020–2026.
    1. Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168:47–54.
    1. Kenny AM, Prestwood KM, Marcello KM, Raisz LG. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci. 2000;55:M492–M497.
    1. Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91(10):3908–39015.
    1. Compston JE. Sex steroids and bone. Physiol Rev. 2001;81(1):419–447.
    1. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503–510.
    1. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20(4):378–387.
    1. Behre HH, Kliesch S, Leifke E, Link TM, Nieschlag E. Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82:2386–2390.
    1. Saggese G, Bertelloni S, Baroncelli GI. Sex steroids and acquisition of bone mass. Horm Res. 1997;48:65–72.
    1. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab. 1999;84:3626–3635.
    1. Holzbeierlein JM, Castle E, Thrasher JB. Complications of androgen deprivation therapy: prevention and treatment. Oncology (Williston Park) 2004;18(3):303–309.
    1. Van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85(9):3276–3282.
    1. Michael H, Härkönen PL, Väänänen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005;20(12):2224–2232.
    1. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092–1098.
    1. Freitas SS, Barrett-Connor E, Ensrud KE, et al. Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int. 2008;19:615–623.
    1. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 2007;298:629–637.
    1. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56:266–272.
    1. De Rosa M, Paesano L, Nuzzo V, et al. Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment. J Endocrinol Invest. 2001;24(4):246–252.
    1. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82:2386.
    1. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol. 1991;38:51–58.
    1. Michal J, Tracz, Sideras K, Bolon ERA. Clinical review: testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 91(6):2011–2016.
    1. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis. Effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18:171–178.
    1. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrniol Metab. 2004;89:503–510.
    1. Bhasin S. regulation of body composition by androgens. J Endocrinol Invest. 2003;26(9):814–822.
    1. Frontera WR, Hughes VV, Fiatarone MA, Fielding RA. Aging and skeletal muscle: a 12 year longitudinal study. J Appl Physiol. 2000;88:1321–1326.
    1. Reed RL, Pearlmutter L, Jochum K, Meredith KE, Mooradian AD. The relationship between muscle mass and muscle strength in the elderly. J Am Geriatr Soc. 1991;39:555–591.
    1. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men; marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998;38(6):1886–1892.
    1. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107:123–136.
    1. Verhaar HJJ, Samson MM, Aleman A, de Vries WR, de Vreede PL, Koppeschaar HPF. The relationship between indices of muscle function and circulating anabolic hormones in healthy. Aging Male. 2000;3:75–80.
    1. Mudali S, Dobs AS. Effects of testosterone on body composition of the aging male. Mech Ageing Dev. 2004;125(4):297–304.
    1. Ferrando AA, Sheffield-Moore M, Paddon-Jones D, Wolfe RR, Urban RJ. Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab. 2003;88:358–362.
    1. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502–1510.
    1. Harman SM, Blackman MR. The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res. 2003;60:121–124.
    1. Tenover JS. Androgen administration in aging men. Endocrinol Metab Clin. 1994;23:877–889.
    1. Urban RJ, Bodenburg C, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995;269:E820–E826.
    1. Sih R, Morley JE, Kaiser FE, Perry HM, III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12 months randomized controlled study. J Clin Endocrinol Metab. 1997;82:1661–1667.
    1. Morley JE, Perry HM, 3rd, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc. 1993;41:149–152.
    1. Perry HM, Miller DK, Patrick P, et al. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49:1085–1091.
    1. Breuer B, Trungold S, Martucci C, et al. Relationship of sex hormone levels to dependence of daily living in the frail elderly. Maturitas. 2001;39:147–159.
    1. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci. 2003;58(11):1002–1008.
    1. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88:2673–2681.
    1. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085–2098.
    1. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999;84:573–577.
    1. Schmidt PJ, Berlin KL, Danaceau MA, et al. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry. 2004;61:997–1004.
    1. Booth A, Johnson DR, Granger DA. Testosterone and men’s depression: the role of social behavior. J Health Soc Behav. 1999;40:130–140.
    1. Kratzik CW, Schatzl G, Lackner JE, et al. Mood changes, body mass index and bioavailable testosterone in healthy men: results of the Androx Vienna Municipality Study. BJU Int. 2007;100:614–618.
    1. Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry. 2001;62(6):406–412.
    1. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–1911.
    1. Reddy P, White CM, Dunn AB, Moyna NM, Thompson PD. The effect of testosterone on health-related quality of life in elderly males: a pilot study. J Clin Pharm Ther. 2000;25:421–426.
    1. Tricker R, Casaburi R, Storer TW, et al. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men: a clinical research center study. J Clin Endocrinol Metab. 1996;81:3754–3758.
    1. Haren MT, Wittert GA, Chapman IM, et al. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low–normal gonadal status. Maturitas. 2005;50:124–133.
    1. Pope HGJ, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. A randomized controlled trial. Arch Gen Psychiatry. 2000;57:133–140.
    1. Su TP, Pagliaro M, Schmidt PJ, et al. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA. 1993;269:2760–2764.
    1. Wang CW, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal menóa clinical research center study. J Clin Endocrinol Metab. 1996;81:3578.
    1. Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. Aging Male. 2007;10:139–153.
    1. Morley JE. Testosterone replacement in older men and women. J Gend Specif Med. 2001;4:49–53.
    1. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003;51:101–115.
    1. Ehrenreich H, Halaris A, Ruether E, et al. Psychoendocrine sequelae of chronic testosterone deficiency. J Psychiatr Res. 1999;33b:379–387.
    1. Heuser I, Hartmann A, Oertel H. Androgen replacement in a 48, XXYY-male patient. Arch Gen Psychiatry. 1999;56:194–195.
    1. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998;48(2–3):157–161.
    1. Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18:20–24.
    1. Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for HIV+ men with and without clinical hypogonadism. J Clin Psychopharmacol. 1999;19:19–27.
    1. Grinspoon S, Corcoran C, Stanley T, et al. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85:60–65.
    1. Seidman SN, Miyazaki M, Roose SP. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J Clin Psychopharmacol. 2005;25:584–588.
    1. Perry PJ, Yates WR, Williams RD, et al. Testosterone therapy in late-life major depression in males. J Clin Psychiatry. 2002;63:1096–1101.
    1. Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry. 2001;50:371–376.
    1. Harkonen K, Huhtaniemi I, Makinen J, et al. The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing men. Int J Androl. 2003;26:187–194.
    1. Amiaz RA, Seidman SN, Stuart NB. Testosterone and depression in men. Curr Opin Endocrinol Diabetes Obes. 2008;15(3):278–283.
    1. Shamlian NT, Cole MG. Androgen treatment of depressive symptoms in older men: a systematic review of feasibility and effectiveness. Can J Psychiatry. 2006;51:295–299.
    1. Kanayama G, Amiaz R, Seidman SN, Pope HGJ. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp Clin Psychopharmacol. 2007;15:529–538.
    1. Gillett MJ, Martins RN, Clarnette RM, Chubb SA, Bruce DG, Yeap BB. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis. 2003;5:267–269.
    1. Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A. 1997;94:7537–7542.
    1. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62:188–193.
    1. Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer’s disease. Exp Gerontol. 2004;39:1633–1639.
    1. McKeever WF, Deyo A. Testosterone, dihydrotestosterone and spatial task performance of males. Bull Psychonomic Soc. 1990;28:305–308.
    1. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999;84:3681–3685.
    1. Yaffe K, Lui L-Y, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002;50:707–712.
    1. Thilers PP, MacDonald SWS, Herlitz A. The association between endogenous free testosterone and cognitive performance: a population-based study in 35–90 year-old men and women. Psychoneuroendocrinology. 2006;31:565–576.
    1. Yeap BB, Almeida OP, Hyde Z, Chubb SAP, Hankey GJ, Jamrozik K, et al. Higher serum free testosterone is associated with better cognitive function in older men, whilst total testosterone is not. The Health In Men Study. Clin Endocrinol. 2008;68:404–412.
    1. Fonda SJ, Bertrand R, O’Donnell A, Longcope C, McKinlay JB. Age, hormones, and cognitive functioning among middle aged and elderly men: cross-sectional evidence from the Massachusetts Male Aging Study. J Gerontol A Biol Sci Med Sci. 2005;60:385–390.
    1. Yonker JE, Eriksson E, Nilsson L-G, Herlitz A. Negative association of testosterone on spatial visualisation in 35 to 80 year old men. Cortex. 2006;42:376–386.
    1. Martin DM, Wittert G, Burns NR, Haren MT, Sugarman R. Testosterone and cognitive function in ageing men: data from the Florey Adelaide Male Ageing Study (FAMAS) Maturitas. 2007;57:182–194.
    1. Burkhardt MS, Foster JK, Clarnette RM, Chubb SAP, Bruce DG, Drummond PD, et al. Interaction between testosterone and apolipoprotein E e4 status on cognition in healthy older men. J Clin Endocrinol Metab. 2006;91:1168–1172.
    1. Chu LW, Tam S, Lee PW, et al. Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf) 2008;68(4):589–598.
    1. Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol. 2003;170:1808–1811.
    1. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004;10:7575–7582.
    1. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29(8):1071–1081.
    1. Hogervorst E, Williams J, Budge M, Barnetson L, Combrinck M, Smith AD. Serum total testosterone is lower in men with Alzheimer’s disease. Neuro Endocrinol Lett. 2001;22(3):163–168.
    1. Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol. 2000;12(4):351–354.
    1. Gibbs RB, Gabor R. Estrogen and cognition: applying preclinical findings to clinical perspectives. J Neurosci Res. 2003;74(5):637–643.
    1. Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol. 2006;155:773–781.
    1. Orwoll ES, Oviatt SK, Biddle J, et al. Transdermal testosterone supplementation in normal older men. Proc 74th Meeting of The Endocrine Soc; San Antonio, TX. 1992. p. 319.
    1. Alexander GM, Swerdloff RS, Wang C, et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. Horm Behav. 1998;33:85–94.
    1. Janowski SC, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108:325–332.
    1. Janowsky JS, Chavez BJ, Orwoll E. Sex steroids modify working memory. Cogn Neurosci. 2000;12:407–414.
    1. Cherrier MM, Craft S, Matsumoto AH. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J Androl. 2003;24:568–576.
    1. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64:2063–2068.
    1. Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63:177–185.
    1. Maki PM, Ernst M, London ED, Mordecai KL, Perschler P, Durso SC, et al. Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function. J Clin Endocrinol Metab. 2007;92:4107–4114.
    1. Tan RS, Culberson JW. An integrative review on current evidence of testosterone replacement therapyfor the andropause. Maturitas. 2003;45:15–27.
    1. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2004;59:75–78.
    1. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25–31.
    1. Makinen J, Jarvisalo MJ, Pollanen P, Perheentupa A, Irjala K, Koskenvuo M, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol. 2005;45:1603–1608.
    1. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, vander Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109:2074–2079.
    1. Tivesten A, Mellstrom D, Jutberger H, Fagerberg B, Lernfelt B, Orwoll E, et al. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol. 2007;50:1070–1076.
    1. Hak AE, Witteman JCM, de Jong FH, Geerlings MI, Hofman A, Pols HAP. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87:3632–3639.
    1. Kapoor D, Clarke S, Channer KS, Jones TH. Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl. 2007;30:500–507.
    1. Ma RC-W, So W-Y, Yang X, Yu LW-L, Kong AP-S, Ko GT-C, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol. 2008;51:2045–2050.
    1. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indices on the sex hormone binding globulin and androgens in aging and obese men. J Clin Endocrinol Metab. 1996;81:1821–1827.
    1. Zumoff B, Strain GW, Miller LK, et al. Plasma free and non sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929–931.
    1. Pasquali R, Casimirri F, Cantobelli S, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991;40:101–104.
    1. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14:226–234.
    1. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III) Diabetes Care. 2007;30:234–238.
    1. Haffner SM, Valdez RA, Stern MP, et al. Obesity, body fat distribution and sex hormones in men. Int J Obes. 1993;17:634–639.
    1. Phillips GB. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism. 2003;52:784–790.
    1. Cohen PG. The hypogonadal-obesity cycle. Med Hypotheses. 1999;52:49–51.
    1. Jones TH. Testosterone associations with erectile dysfunction, diabetes and the metabolic syndrome. Eur Urol (Suppl) 2007;6:847–857.
    1. Er F, Michels G, Gassanov N, Rivero F, Hoppe UC. Testosterone induces cytoprotection by activating ATPsensitive Kþ channels in the cardiac mitochondrial inner membrane. Circulation. 2004;110:3100–3107.
    1. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse. Circulation. 2007;116:2427–2434.
    1. Kalme T, Seppala M, Qiao Q, et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90:1550–1556.
    1. Kupelian V, Page ST, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843–850.
    1. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006;65:125–131.
    1. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab. 2007;92:3568–3572.
    1. Simon D, Preziosi P, Barrett-Connor E, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia. 1992;35:173–177.
    1. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men: a prospective population-based study. Circulation. 1988;78:539–545.
    1. Pitteloud N, Mootha VK, Dwyer AA, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005;28:1636–1642.
    1. Münzer T, Harman SM, Christmas C, et al. Effects of administration of testosterone and/or GH in healthy aged men [abstract]. Aging Male; Presented at 2nd World Congress on the Aging Male; Geneva, Switzeland. 2000; 2000. p. 3.
    1. Abate N, Haffner SM, Garg A, et al. Sex steroid hormones, upper body obesity and insulin resistance. J Clin Endocrinol Metab. 2002;87:4522–4527.
    1. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.
    1. Corrales JJ, Burgo RM, Garca-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004;53:666–672.
    1. Basu R, Dalla MC, Campioni M, et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care. 2007;30:1972–1978.
    1. Tenover JL. Effects of androgen supplementation in aging males. In: Oddens B, Vermeulen A, editors. Androgens and the aging male. New York, London: Parthenon Publishing Group; 1996. pp. 191–204.
    1. Haffner JM. Androgens in relation to cardiovascular disease and insulin resistance in aging men. In: Oddens B, Vermeulen A, editors. Androgens and the aging male. New York, London: Parthenon Publishing Group; 1996. pp. 65–84.
    1. Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high density lipoprotein concentration following complete androgen blockade in men with prostatic carcinoma. Metabolism. 1987;36:244–250.
    1. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001;111:261–269.
    1. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(6):634.
    1. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469–3478.
    1. Marin P, Holmäng S, Gustafson C, et al. Androgen treatment of abdominally obese men. Obesity Res. 1993;1:245–248.
    1. Marin P, Lonn B, Andersson B, Oden B, Olbe L, Bengtsson BA. Assimilation of triglycerides in subcutaneous and intra-abdominal adipose tissues in vivo in men. J Clin Endocrinol Metab. 1996;81:1018–1022.
    1. Xu X, De Pergola G, Bjorntorp P. Testosterone increases lipolysis and the number ß-adrenoreceptors in male rat adipocytes. Endocrinology. 1991;128:379–381.
    1. Marin P, Oden B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80:239–243.
    1. Zmuda JM, Fahrenbach MC, Younkin BT, et al. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism. 1993;42:446–450.
    1. Jacobs DR, Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32–47.
    1. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87:136–143.
    1. Phillips G, Pinkernell BH, Jing TY. The association between hypotestosteronemia and coronary heart disease in men. Arterioscler Thromb. 1994;14:701–706.
    1. Vermeulen A, Goemaere S, Kaufman JM. Sex hormones, body composition and aging. Aging Male. 1999;2:8–15.
    1. Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897–901.
    1. Tchernof A, Labrie F, Belanger A, et al. Relationships between endogenous sex steroid hormones, sex hormone binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis. 1997;133:235–244.
    1. Kannell WB, Cupples LA, Ramaswami R, Stokes J, Jr, Kreger BE, Higgings M. Regional obesity and the risk of coronary disease: The Framingham Study. J Clin Epidemiol. 1991;44:183–190.
    1. Björntorp P. Visceral obesity: a civilisation syndrome. Obes Res. 1993;1:206–222.
    1. Kabakci G, Yildirir A, Can I, Unsal I, Erbas B. Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology. 1999;92:221–225.
    1. Haddad RM, Kennedy CC, Caples SM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):11–13.
    1. Allan CA, McLachlan RI. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol. 2004;60:653–670.
    1. Haffner JE, Moss SE, Klein BEK, Klein R. Sex hormones and DHEASO4 in relation to ischemic heart disease in diabetic subjects. The WESDR Study. Diabetes Care. 1996;19:1045–1050.
    1. Barrett-Connor E, Khaw KS. Endogenous sex hormone levels and cardiovascular disease in men: a prospective population based study. Circulation. 1988;788:539–543.
    1. Cauley JA, Gutai JP, Kuller LH, Dai WS. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol. 1987;60:771–777.
    1. Goldberg RB, Rabin AN, Alexander AN, Doelle GC, Getz GS. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and Apo A and B. J Clin Endocrinol Metab. 1985;60:203–207.
    1. Caron P, Bennet A, Camare L, Louvet JP, Boneu S, Sie P. Plasminogen activator inhibitor in plasma is related to testosterone in man. Metabolism. 1989;38:1010–1013.
    1. Polderman KH, Stehouwer CDA, van de Kamp GJ, Dekker GH, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118:429–431.
    1. Ajayi AA. Testosterone increases platelet thromboxane A2 receptor density. Circulation. 1995;91:2740–2747.
    1. Spivak JL. The blood in systemic disorders. Lancet. 2000;355:1707–1712.
    1. Zitzmann M, Nieschlag E. Androgens and erythropoiesis. In: Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Cambridge: Cambridge University Press; 2004. pp. 283–296.
    1. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2369–2371.
    1. Holyoak JD, Crawford ED, Meacham RB. testosterone and the testosterone: implications for the treatment of hypogonadal men. Curr Urol Rep. 2008;9:500–505.
    1. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–83.
    1. Carpenter WR, Robinson WR, Godley PA. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst. 2008;100:158–159.
    1. Holmäng S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone-undecanoate treatment on prostatic volume and serum prostate specific antigen in eugonadal middle-aged men. Prostate. 1993;23:99–106.
    1. Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5a-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab. 1993;77:375–381.
    1. Slater S, Oliver RTD. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging. 2000;17:431–439.
    1. Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002;25:119–125.
    1. Curran MJ, Bihrle W., III Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology. 1999;53:423–424.
    1. Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol. 1997;157:1845.
    1. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170(6 pt 1):2348–2351.
    1. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670–2677.
    1. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 1995;27:25–31.
    1. Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999;86:312–315.
    1. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–536.
    1. Ferreira U, Leitao VA, Denardi F, Matheus WE, Stopiglia RM, Netto NR., Jr Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients. Prostate Cancer Prostatic Dis. 2006;9:39–41.
    1. Weiss JM, Huang WY, Rinaldi S. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer. 2008;122(10):2345–2350.
    1. Fowler JE, Jr, Whitmore WF., Jr Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer. 1982;49:1373–1377.
    1. McConnell JD. Prostatic growth: new insights into hormonal regulation. Br J Urol. 1995;76(Suppl 1):5–10.
    1. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–541.
    1. Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am. 2007;34:549–553.
    1. Swerdloff RS, Wang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male. 2003;6:207–211.
    1. El-Sakka AI, Hassoba HM, Elbakry AM, Hassan HA. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005;2:235–240.
    1. Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006;18:201–205.
    1. Kuhnert B, Byrne M, Simoni M, et al. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol. 2005;153:317–326.
    1. Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006;68:1152–1155.
    1. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529–534.
    1. Thompson IM, Carroll PR, Carducci MA. Recommendations for defining and treating high risk localized prostate cancer. J Urol. 2006;176:S6–S10.
    1. Summary from the second annual andropause consensus meeting; Chevy Chase, Md: Endocrine Society; 2001.
    1. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24:299–311.
    1. Rhoden EL, Averbeck MA, Teloken PE. Androgen replacement in men undergoing treatment for prostate cancer. J Sex Med. 2008;5(9):2202–2208.
    1. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet. 1977;2:262–263.
    1. Gurakar A, Caraceni P, Fagiuoli S, Van Thiel DH. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J Okla State Med Assoc. 1994;87:399–404.
    1. Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver. 1992;12:73–79.
    1. Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging. 1999;15:131–142.
    1. The Endocrine Society Clinical bulletins in andropause: benefits and risks of treating hypogonadism in the aging male. Endocr Rep. 2002;2:1–6.
    1. Kim YC. Testosterone supplementation in the aging male. Int J Impot Res. 1999;11:343–352.
    1. Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol. 2000;110:237–238.
    1. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc. 1995;43:899–901.
    1. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006;65:275–281.
    1. Uzych L. Anabolic-androgenic steroids and psychiatric-related effects: a review. Can J Psychiatry. 1992;37:23–28.
    1. Bahrke MS, Yesalis CE, III, Wright JE. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males: a review. Sports Med. 1990;10:303–337.
    1. Bagatell CJ, Bremner WJ. Androgens in men – uses and abuses. N Engl J Med. 1996;334:707–714.
    1. World Health Organization Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990;336:955.
    1. World Health Organization Contraceptive efficacy of testosterone-induced azoospermia and oligozoopermia in normal men. Fertil Steril. 1996;65:821.
    1. Wilson JD. Androgen abuse by athletes. Endocr Rev. 1988;9:181–199.
    1. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, Lavie P. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab. 2002;87:3394–3398.
    1. Schneider BK, Pickett CK, Zwillich CW, et al. Influence of testosterone on breathing during sleep. J Appl Physiol. 1986;61:618–623.
    1. Matsumoto AM, Sandblom RE, Schoene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985;22:713–721.
    1. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl. 2002;23:419–425.
    1. Tangredi JF, Buxton LL. Hypertension as a complication of topical testosterone therapy. Ann Pharmacother. 2001;35:1205–1207.
    1. de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod. 2009;24(2):425–428.
    1. Cunningham GR. Testosterone replacement therapy for late-onset hypogonadism. Nat Clin Pract Urol. 2006;3(5):260–267.
    1. Cunningham GR. Male hypogonadism: management strategies. News and views on male testosterone deficiency. A Supplement to Renal &Urology News. 2006;1(3)
    1. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007;36(6):333–348.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner